By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Metabolex, Inc. 

3876 Bay Center Place

Hayward  California  94545  U.S.A.
Phone: 510-293-8800 Fax: 510-293-9090




Yamanouchi Pharmaceutical Co., Ltd. 


Devgen NV  Signed in 2001; research collaboration focused on diabetes; both companies each employ their respective technologies to identify each others compounds' mechanism of action.

Company News
Metabolex, Inc. Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat 12/8/2011 7:19:24 AM
Metabolex, Inc. Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch 11/29/2011 12:22:32 PM
Metabolex, Inc. to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011ACR/ARHP Annual Scientific Meeting 11/1/2011 10:43:57 AM
Metabolex, Inc. Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer 10/20/2011 11:29:40 AM
Metabolex, Inc. Initiates Phase 2 Trial of Arhalofenate 5/19/2011 9:00:36 AM
Sanofi-Aventis (France) (SASY.PA) Opts Out of Metabolex, Inc. Diabetes Drug Deal; Deal Could Have Been Worth up to $375 Million 5/6/2011 7:24:55 AM
Metabolex, Inc. to Conduct a Webcast of Its Second Quarter 2010 Earnings Call 7/16/2010 10:14:16 AM
Sanofi-Aventis (France) (SASY.PA) Inks $375 Million Diabetes Deal With Metabolex, Inc. 6/25/2010 6:53:18 AM
Metabolex, Inc. Enters Into Type 2 Diabetes Development and License Agreement with Ortho-McNeil Pharmaceutical, Inc.; Metabolex Could be Eligible to Receive Development, Regulatory, and Commercial Milestones up to $330 Million 6/22/2010 7:15:21 AM
Metabolex, Inc. Initiates Research Collaboration with Takeda Pharmaceutical Co. Ltd. (TKDG.DE) 4/13/2010 9:19:26 AM